FDA Launches Pilot Program To Streamline EtO Facility, Process Changes

As concerns continue to mount over a potential shortage of medical devices due to the closure of ethylene oxide (EtO) facilities, the US agency is looking for nine sterilizers in a pilot project that could allow them to get facility and process changes approved faster.

FDABldg1ExteriorWithCircle_1200x675

Some medtech manufacturers could get their products approved sooner for sterilization using different ethylene oxide (EtO) plants and/or less ethylene oxide if the sterilizing company they use participates in a new pilot project.

On 25 November, the US Food and Drug Administration announced it is looking for volunteers to participate in its Master...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

Second Slovenian Notified Body Named Under EU’s Medical Device Regulation

 

New notified body is listed under the EU Medical Device Regulation after no designations for a year.

Case Study: Pushing The EU’s IVD Regulation To Its Limits With Next Generation Sequencing

 

Partnership, positive communication and passion were all key in establishing a regulatory route for groundbreaking genetic testing technology for hereditary diseases. So said Fulgent Genetics’ executives interviewed by MTI about their technology’s development pathway.

EU Begins To Define Secondary Uses Of Health Data Under EHDS

 

The medtech industry, eagerly awaiting clear guidance on how healthcare data can be shared and help drive innovation, can have its say.

Should the EU Allow eIFU For Some Lay Devices?

 

Electronic instructions for use are becoming increasingly prevalent in the medtech world, but so far in the EU do not extend to non-professional users.

More from Policy & Regulation

Case Study: Pushing The EU’s IVD Regulation To Its Limits With Next Generation Sequencing

 

Partnership, positive communication and passion were all key in establishing a regulatory route for groundbreaking genetic testing technology for hereditary diseases. So said Fulgent Genetics’ executives interviewed by MTI about their technology’s development pathway.

Biolinq Aims To ‘Shine’ In Early 2026 With Needle-Free CGM US Debut, Human Data On Protein Sensor

 
• By 

Fresh off de novo clearance, Biolinq plans to launch its needle-free CGM for type 2 diabetes not on insulin in early 2026. Pricing has not been disclosed, but “won’t be too far apart” over rivals Abbott’s Lingo and Dexcom’s Stelo CGMs, CEO Rich Yang said.

Blood Volume, Reimagined: Daxor’s BVA Could Slash Testing Time and Save Lives

 
• By 

The Daxor Blood Volume Analysis (BVA) is aimed at improving care for heart failure patients. It will allow blood volume to be measured from the patient’s bedside for the first time and is also significantly faster than earlier testing methods.